Author

Zsuzsanna Bata-Csörgő

University of Szeged - Cited by 6,652

Biography

Zsuzsanna Bata-Csorgo is currently working as Professor at Department of Dermatology and Allergology, University of Szeged, Albert Szent-Györgyi Medical Center, Hungary. Her research interest is based on Allergic Skin disease, Inflamatory Skin diseases and Autoimmune sskin diseases. She has published many articles in reputed journals.
Title
Cited by
Year
Exosomal long non-coding RNAs as biomarkers in human diseases
E Kelemen, J Danis, A Göblös, Z Bata-Csörgő, M SzéllEjifcc 30 (2), 224, 2019201
44
2019
Trial of intravenous immune globulin in dermatomyositis
R Aggarwal, C Charles-Schoeman, J Schessl, Z Bata-Csörgő, ...New England Journal of Medicine 387 (14), 1264-1278, 2022202
41
2022
Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open‐label feasibility trial
M Goebeler, Z Bata‐Csörgő, C De Simone, B Didona, E Remenyik, ...British Journal of Dermatology 186 (3), 429-439, 2022202
30
2022
Comprehensive proteomic analysis reveals intermediate stage of non-lesional psoriatic skin and points out the importance of proteins outside this trend
E Szél, R Bozó, É Hunyadi-Gulyás, M Manczinger, K Szabó, L Kemény, ...Scientific Reports 9 (1), 11382, 2019201
22
2019
DLQI‐R scoring improves the discriminatory power of the Dermatology Life Quality Index in patients with psoriasis, pemphigus and morphea
F Rencz, L Gulácsi, M Péntek, A Szegedi, É Remenyik, Z Bata‐Csörgő, ...British Journal of Dermatology 182 (5), 1167-1175, 2020202
21
2020
Disease burden of patients with pemphigus from a societal perspective
V Brodszky, B Tamási, K Hajdu, M Péntek, A Szegedi, M Sárdy, ...Expert review of pharmacoeconomics & outcomes research 21 (1), 77-86, 2021202
16
2021
Dermatology Life Quality Index (DLQI) score bands are applicable to DLQI-Relevant (DLQI-R) scoring
F Rencz, LH Gergely, N Wikonkál, K Gáspár, M Péntek, L Gulácsi, ...Journal of the European Academy of Dermatology and Venereology: JEADV 34 (9 …, 2020202
12
2020
Patient‐assigned health utility values for controlled and uncontrolled pemphigus vulgaris and foliaceus
K Hajdu, V Brodszky, PFM Stalmeier, G Ruzsa, B Tamási, L Gulácsi, ...Journal of the European Academy of Dermatology and Venereology 33 (11), 26 …, 2019201
10
2019
Recurrent, Severe Aphthous Stomatitis and Mucosal Ulcers as Primary Manifestations of a Novel STAT1 Gain-of-Function Mutation
M Erdős, E Jakobicz, B Soltész, B Tóth, Z Bata-Csörgő, L MaródiFrontiers in immunology 11, 967, 2020202
10
2020
Subjective well-being in patients with pemphigus: a path analysis
A Mitev, F Rencz, B Tamási, K Hajdu, M Péntek, L Gulácsi, A Szegedi, ...The European Journal of Health Economics 20, 101-107, 20120
9
2019
Efficacy and safety of IVIg (octagam 10%) in patients with active dermatomyositis. Results of a randomized, double-blind, placebo-controlled phase III trial (ProDERM study)
R Aggarwal, C Charles-Schoeman, J Schessl, Z Bata-Csorgo, ...ARTHRITIS & RHEUMATOLOGY 72, 2020202
8
2020
Could basement membrane alterations, resembling micro‐wounds at the dermo‐epidermal junction in psoriatic non‐lesional skin, make the skin susceptible to lesion formation?
R Bozó, LB Flink, N Belső, B Gubán, M Széll, L Kemény, Z Bata‐CsörgőExperimental Dermatology 30 (6), 65-2, 2021202
7
2021
Cartilage oligomeric matrix protein negatively influences keratinocyte proliferation via α5β1-Integrin: Potential relevance of altered cartilage oligomeric matrix protein …
R Bozó, E Szél, J Danis, B Gubán, Z Bata-Csörgő, K Szabó, L Kemény, ...Journal of Investigative Dermatology 140 (9), 133-142. e, 2020202
7
2020
FcRn antagonism leads to a decrease of desmoglein-specific B cells: secondary analysis of a phase 2 study of efgartigimod in pemphigus vulgaris and pemphigus foliaceus
M Maho-Vaillant, M Sips, ML Golinski, G Vidarsson, M Goebeler, ...Frontiers in Immunology 13, 863095, 2022202
7
2022
Op0008 a randomized, double-blind, placebo-controlled phase iii trial of Ivig 10% in patients with dermatomyositis. The Proderm Study: results on efficacy and safety
R Aggarwal, C Charles-Schoeman, J Schessl, Z Bata-Csorgo, ...Annals of the Rheumatic Diseases 80 (Suppl 1), 4-5, 2021202
6
2021
Stress-related regulation is abnormal in the psoriatic uninvolved skin
R Bozó, J Danis, LB Flink, DL Vidács, L Kemény, Z Bata-CsörgőLife 11 (7), 99, 2021202
5
2021
Phenotypic plasticity of melanocytes derived from human adult skin
DL Vidács, Z Veréb, R Bozó, LB Flink, H Polyánka, IB Németh, S Póliska, ...Pigment Cell & Melanoma Research 3 (1), 38-1, 2022202
5
2022
The psoriatic nonlesional skin: a battlefield between susceptibility and protective factors
E Kelemen, R Bozó, G Groma, Z Bata-Csörgő, L Kemény, J Danis, M SzéllJournal of Investigative Dermatology 11 (12), 2785-2790, 2021202
4
2021
Psoriatic Resolved Skin Epidermal Keratinocytes Retain Disease-Residual Transcriptomic and Epigenomic Profiles
A Ghaffarinia, F Ayaydin, S Póliska, M Manczinger, BS Bolla, LB Flink, ...International Journal of Molecular Sciences 4 (5), 4556, 030
2
2023
Anti‐interleukin‐6 receptor therapy‐induced cutaneous symptoms resembling purpura fulminans in a patient with seropositive rheumatoid arthritis
GR Nagy, E Varga, L Kovács, I Németh, E Varga, L Kemény, ...Journal of the European Academy of Dermatology and Venereology 34 (9), e53-e54, 000
2
2020

Referred From: https://scholar.google.com/citations?user=N6RvGuUAAAAJ&hl=en

Cited by
Citations 6652
h-index 34
i10-index 75
Recommended Journals
Open Access Journals